Compare Ascendis Pharma A/S (ASND) vs Sony Group Corp (SONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Sony Group Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Sony Group Corp trades at $20.64 (market cap $121.92B). The key difference: Sony Group Corp is far larger — about 6.9× Ascendis Pharma A/S's market cap, and Sony Group Corp pays a 0.76% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SONY | |
|---|---|---|
Market Cap | $17.74B | $121.92B |
Sector | Health | Technology |
52-Week High | $277.18 | $30.26 |
52-Week Low | $163.32 | $19.32 |
Enterprise Value | $18.11B | $118.41B |
Dividend Yield | — | 0.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Sony trades at $20.85, down 0.38% on the day, with a neutral technical signal. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company reported strong operating cash flow of $2.32 trillion in 2025, though net income margin remains negative at -2.62%. Key news includes Sony's plan to phase out PlayStation physical discs by 2028 and conditional approval for a U.S. stablecoin bank.
Outlook is cautiously optimistic with 69% analyst buy ratings, but risks include execution of digital transition and projected negative net income in 2026. The stock's valuation appears reasonable with a P/E of 19.68, but investors should monitor earnings consistency and market reception to strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
